Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: Roles of p53 and caspase activation

Journal of Cellular Biochemistry

Volumn 78, Issue 2, 2000, Pages 334-349

  Liu, Yongmin ^a,b   McKalip, Ann ^a,c   Herman, Brian ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UTHSCSA ^*  (United States)

Author keywords

Apoptosis; Caspases; DNA damage; Human papillomavirus; p53

Indexed keywords

ANTIINFECTIVE AGENT; ATRACTYLOSIDE; BUTYRIC ACID; CASPASE; CISPLATIN; ETOPOSIDE; MITOMYCIN C; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE INDUCTION; GENE LOCATION; HUMAN; HUMAN CELL; KERATINOCYTE; NEWBORN; PRIORITY JOURNAL; SENSITIZATION; WART VIRUS;

DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; HUMAN POLIOVIRUS 1;

EID: 0034088038     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(20000801)78:2<334::AID-JCB15>3.0.CO;2-F     Document Type: Article

References (56)

1. Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, Bertino JR, Wahl GM. 1995. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci USA 92:5436-5440.
2. Brown J, Higo H, McKalip A, Herman B. 1997. Human papillomavirus (HPV) 16 E6 sensitizes cells to atractyloside-induced apoptosis: role of p53, ICE-like proteases and the mitochondrial permeability transition. J Cell Biochem 66:245-255.
3. Butz K, Shahabeddin L, Geisen C, Spitkovsky D, Ullmann A, Hoppe-Seyler F. 1995. Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 10: 927-936.
4. Cadlles C, Helmbery A, Karin M. 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370:220-223.
5. Chandler JM, Alnemri ES, Cohen GM, Macfarlane M. 1997. Activation of CPP32 and Mch3a in wild-type p53-induced apoptosis. Biochem J 322:19-23.
6. Chen X, Ko LJ, Jayaraman L, Prives C. 1996. p53 levels, functions domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10:2438-2451.
7. Crook T, Wrede D, Tidy J, Scholefield J, Crawford L, Vousden KH. 1991a. Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene 6:1251-1257.
8. Crook T, Wrede D, Vousden KH. 1991b. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6:1353-1356.
9. Cryns V, Yuan J. 1998. Proteases to die for. Genes Dev 12:1551-1570.
10. Demers GW, Espling E, Harry JB, Etsheid BG, Galloway DA. 1996. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol 70:6862-6869.
11. Demers AW, Halbert CL, Galloway DA. 1994. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology 198:169-174.
12. Ding HF, McGill G, Rowan S, Schmaltz C, Shimamura A, Fisher DE. 1998. Oncogene-dependent regulation of caspase activation by p53 protein in a cell-free system. J Biol Chem 273:28378-28383.
13. Foster SA, Demers GW, Etscheid BG, Galloway DA. 1994. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlated with their ability to abrogate actinomycin D-induced growth arrest. J Virol 68:5698-5705.
14. Fuchs EJ, McKenna KA, Bedi A. 1997. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32b. Cancer Res 57:2550-2554.
15. Gao C, Tsuchida N. 1999. Activation of caspases in p53-induced transactivation-independent apoptosis. Jpn J Cancer Res 90:180-187.
16. Galloway DA, McDougall JK. 1996. The disruption of cell cycle checkpoints by papillomavirus oncoproteins contribute to anogenital neoplasia. Semin Cancer Biol 7:309-315.
17. Haupt Y, Rowan S, Shaulian E, Vousden, KH, Oren M. 1995. Induction of apoptosis in HeLa cells by transactivation-deficient p53. Genes Dev 9:2170-2183.
18. Hawkins DS, Demers GW, Galloway DA. 1995. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-895.
19. Hickman ES, Bates S, Vousden KH. 1997. Perturbation of the p53 response by human papillomavirus type 16 E7. J Virol 71:3710-3718.
20. Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, Cleveland JL. 1995. E2F-1: DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol 15:6864-6874.
21. Hwang JK, Lin CT. 1997. Co-localization of endogenous and exogenous p53 proteins in nasopharyngeal carcinoma cells. J Histochem Cytochem 45:991-1003.
22. Isaacs JS, Hardman R, Carman TA, Barrett JC, Weissman BE. 1998. Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines. Cell Grow Differ 9:545-555.
23. Ishiwatari H, Hayasaka N, Inoue H, Yutsudo M, Hakura A. 1994. Degradation of p53 only is not sufficient for the growth stimulatory effect of human papillomavirus 16 E6 oncoprotein in human embryonic fibroblasts. J Med Virol 44:243-249.
24. Johnson MD, Kinoshita Y, Xiang H, Ghatan S, Morrison RS. 1999. Contribution of p53-dependent caspase activation to neuronal cell death declines with neuronal maturation. J Neurosci 19:2996-3006.
25. Jones DL, Munger KL. 1997. Analysis of the p53-mediated growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 71:2905-2912.
26. Kessis TD, Connolly DC, Hedrick L, Cho KR. 1996. Expression of HPV-16 E6 or E7 increases integration of foreign DNA. Oncogene 13:427-431.
27. Knippschild U, Oren M, Deppert W. 1996. Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion. Oncogene 12:1755-1765.
28. Ko LJ, Prives C. 1996. P53: Puzzle and paradigm. Genes Dev 10:1054-1072.
29. Kovacs A, Weber ML, Burns LJ, Jacob HS, Vercellottj GM. 1996. Cytoplasmic sequestration of p53 in cytomegalovirus-infected human endothelial cells. Am J Pathol 149:1531-1539.
30. 2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ 8:1105-1111.
31. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
32. Liang XH, Volkmann M, Klein R, Herman B, Lockett SJ. 1993. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines. Oncogene 8:2645-2652.
33. Liu Y, Tergaonkar V, Krishna S, Androphy EJ. 1999. Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor α correlates with increased accumulation of reactive oxygen species. J Biol Chem 274:24819-24827.
34. Liu X, Han S, Baluda MA, Park NH. 1997. HPV-16 oncogenes E6 and E7 are mutagenic in normal human oral keratinocytes. Oncogene 14:2347-2353.
35. Lochmuller H, Johns T, Shoubridge EA. 1999. Expression of E6 and E7 genes of human papillomavirus (HPV-16) extends the lifespan of human myoblasts. Exp Cell Res 248:186-193.
36. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. 1996. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 16:1126-1137.
37. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. 1994. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371:72-74.
38. Nakagawa S, Watanabe S, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. 1995. Mutational analysis of human papillomavirus type 16 E6 protein: Transforming function for human cells and degradation of p53 in vitro. Virology 212(2):535-542.
39. Pan H, Griep AE. 1995. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev 9:2157-2169.
40. Pfister H. 1996. The role of human papillomavirus in anogenital cancer. Obst Gynecol 23:79-595.
41. Scheffner M, Munger K, Byrne JC, Howley PM. 1991. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 88:5523-5527.
42. Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW. 1999. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284:156-158
43. Storey A, Massimi P, Dawson K, Banks L. 1995. Conditional immortalization of primary cells by human papillomavirus type 18 E6 and EJ-ras defines an E6 activity in G0/G1 phase which can be substituted for mutations in p53. Oncogene 11:653-661.
44. Thomas M, Matlashewski G, Pim D, Banks L. 1996. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 13:265-273.
45. Thornberry NA, Lazebnik Y. 1998. Caspases: Enemies within. Science 281:1312-1316.
46. Turner PC, Moyer RW. 1998. Control of apoptosis by pox-viruses. Semin Virol 8:453-469.
47. wafl/cip1. Genes Dev 8:2817-2830.
48. Wan TS, Martens UM, Poon SS, Tsao SW, Chan LC, Lansdorp PM. 1999. Absence of low number of telomere repeats at junctions of dicentric chromosomes. Genes Chromo Cancer 24:83-86.
49. Wang Y, Okan I, Pokrovskaja K, Wiman KG. 1996. Abrogation of p53-induced G1 arrest by the HPV-16 E7 protein does not inhibit p53-induced apoptosis. Oncogene 12:2731-2735.
50. White ET, Grodzicker T, Stillman BW. 1984. Mutations in the gene encoding the adenovirus E1B 10K tumor antigen causes degradation of chromosomal DNA. J Virol 52:410-419.
51. Wu X, Levine AJ. 1994. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91:3602-3606.
52. Xu C, Meikrantz W, Schlegel R, Sager R. 1995. The human papillomavirus 16 E6 gene sensitizes human mammary cells to apoptosis induced by DNA damage. Proc Natl Acad Sci USA 92:7829-7833.
53. Yu Y, Little JB. 1998. p53 is involved in but not required for ionizing radiation-induced caspase-3 activation and apoptosis in human lymphoblast cell lines. Cancer Res 58:4277-4281.
54. Yu Y, Li C-Y, Little JB. 1997. Abrogation of p53 function by HPV 16 E6 gene delays apoptosis and enhances mutagenesis but does not alter radiosensitivity in TK6 human lymphoblast cells. Oncogene 14:1661-1667.
55. Zehbe I, Ratsch A, Alunni-Fabbroni M, Burzlaff A, Bakos E, Durst M, Wilander E, Tommasino M. 1999. Over-riding the cyclin-dependent kinase inhibitors by high and low risk human papillomavirus types: Evidence for an in vivo role in cervical lesions. Oncogene 18: 2201-2211.
56. Zur Hausen H. 1996. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1288: F55-78.